NCT00085280View on ClinicalTrials.gov

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NACompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2006

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00085280 - Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter